Climb Bio announces Phase 1 data for CLYM116 demonstrates deep APRIL suppression and 12-week dosing interval.
Early clinical data for anti-APRIL antibody CLYM116/MIL116 showed sustained ~90% suppression of APRIL and 12-week dosing support, with Phase 2 and 3 trials scheduled starting 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed